Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- QGEN Qiagen N.V
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Qiagen N.V belongs to, so it often moves with news about it.
- BNTX BioNTech SE-12.0% 13d
BioNTech SE is a peer of Qiagen N.V in biological products, (no diagnostic substances); rivals often move on the same news.
- NBIX Neurocrine Biosciences
Neurocrine Biosciences is a peer of Qiagen N.V in biological products, (no diagnostic substances); rivals often move on the same news.
- CRSP CRISPR Therapeutics AG-14.3% 30d
CRISPR Therapeutics AG is a peer of Qiagen N.V in biological products, (no diagnostic substances); rivals often move on the same news.
- AMGN Amgen+13.5% 30d
Amgen is a peer of Qiagen N.V in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+11.0% 30d
Gilead Sciences is a peer of Qiagen N.V in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| QGEN | -0.90% | -0.94% | base | after close | after close | after close | after close |
| XLV | -2.96% | -2.66% | base | after close | after close | after close | after close |
| BNTX | -1.77% | -3.52% | base | after close | after close | after close | after close |
| NBIX | -11.84% | -12.44% | base | after close | after close | after close | after close |
| CRSP | +4.78% | -3.51% | base | after close | after close | after close | after close |
| AMGN | -3.66% | -2.64% | base | after close | after close | after close | after close |
| GILD | -5.08% | -2.33% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| AMGN | three days earlier | -2.64% | final price |
| AMGN | five days earlier | -3.66% | final price |
| BNTX | three days earlier | -3.52% | final price |
| BNTX | five days earlier | -1.77% | final price |
| CRSP | three days earlier | -3.51% | final price |
| CRSP | five days earlier | +4.78% | final price |
| GILD | three days earlier | -2.33% | final price |
| GILD | five days earlier | -5.08% | final price |
| NBIX | three days earlier | -12.44% | final price |
| NBIX | five days earlier | -11.84% | final price |
| QGEN | three days earlier | -0.94% | final price |
| QGEN | five days earlier | -0.90% | final price |
| XLV | three days earlier | -2.66% | final price |
| XLV | five days earlier | -2.96% | final price |
Congressional trades in the stocks in this story
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 44 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 71 days before publication. Filed 5 Sep 2026. View the filing.
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $1,001 - $15,000 on 12 Aug 2026. That is 85 days before publication. Filed 2 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 87 days before publication. Filed 4 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics” scores 12 out of 100. The score uses 1 sources.